Bioinformatic analysis of patient databases conducted by Fei et al. [24] showed that EGR4 levels are significantly lower in triple negative breast cancer patients, and that EGR4 is downregulated with metastatic breast cancer (i.e., when nodule status was positive). Here, EGR4 is linked to triple-negative breast carcinoma.